RT Journal Article SR Electronic T1 Management of Challenging Radioiodine Treatment Protocols: A Case Series and Review of the Literature JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 180 OP 185 DO 10.2967/jnmt.120.255307 VO 49 IS 2 A1 Joseph Waller A1 Courtney A. Lawhn-Heath A1 Cathleen Edmonds A1 Chloee Wendorf A1 Brandon Holmes A1 Michael White A1 Miguel Hernandez Pampaloni A1 Chienying Liu A1 Robert R. Flavell YR 2021 UL http://tech.snmjournals.org/content/49/2/180.abstract AB Radioactive iodine (RAI) therapy with 131I is the standard of care for treatment in many patients with differentiated thyroid cancer. Because 131I is typically administered as a pill, and much of its radioactivity is excreted via the urine, there can be challenges in patients who cannot swallow pills, absorb iodine via the gastrointestinal tract, or eliminate RAI via the urine (i.e., dialysis patients and patients with renal failure). In this article, we present 3 cases in which the standard 131I treatment protocol for thyroid cancer could not be used because of these challenges, and we discuss the strategies used to overcome them. Provider collaboration and treatment customization are critical in overcoming patient-specific challenges.